The in vivo knockdown of this upregulated protein using profilin-1 siRNA-loaded into inorganic NPs (i.e., gold NPs) was demonstrated to reduce the proliferation and migration of smooth muscle cells and improve the therapeutic efficiency in the atherosclerosis model [242]. This evidence concerns the gene PFN1 and atherosclerosis.